000			02351 a2200613 4500
005			20250515131309.0
264		0	_c20090217
008			200902s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdn427 _2doi
040			_aNLM _beng _cNLM
100	1		_aPeintinger, F
245	0	0	_aHormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cDec 2008
300			_a2020-5 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDoxorubicin
650	0	4	_aEpirubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aNeoplasm, Residual _xprevention & control
650	0	4	_aNeoplasms, Hormone-Dependent _xdrug therapy
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptor, ErbB-2 _xbiosynthesis
650	0	4	_aReceptors, Estrogen _xmetabolism
650	0	4	_aReceptors, Progesterone _xmetabolism
650	0	4	_aTrastuzumab
700	1		_aBuzdar, A U
700	1		_aKuerer, H M
700	1		_aMejia, J A
700	1		_aHatzis, C
700	1		_aGonzalez-Angulo, A M
700	1		_aPusztai, L
700	1		_aEsteva, F J
700	1		_aDawood, S S
700	1		_aGreen, M C
700	1		_aHortobagyi, G N
700	1		_aSymmans, W F
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 19 _gno. 12 _gp. 2020-5
856	4	0	_uhttps://doi.org/10.1093/annonc/mdn427 _zAvailable from publisher's website
999			_c18143916 _d18143916